The front page of AI-driven biology
Thursday, October 22, 2026Thu, Oct 22
Updated 12:03 PM PT
In combination with Merck's anti-PD-1 checkpoint inhibitor pembrolizumab (Keytruda), Moderna's individualized neoantigen mRNA vaccine cut the risk of recurrence or death by 42% in patients with resected high-risk melanoma.
Former OpenAI science lead Kevin Weil launched Warp Sciences with a $215 million funding round at an $865 million valuation led by Lightspeed, alongside IVP, Premji Invest, and Lux Capital.
In simulated diagnostic trials using complex case reports from the New England Journal of Medicine, Microsoft AI's multi-agent system, MAI-DxO, reached an accurate diagnosis in 83% of cases compared to 36% for individual primary care physicians and general internists.
In a prospective study of over 2,500 men from the EPIC cohort, researchers at Oxford Population Health identified circulating proteins linked to known prostate cancer driver genes that were detectable up to ten years before diagnosis.
The Food and Drug Administration launched the Neuroscience Advancement and Innovation Nexus, an inter-center initiative designed to streamline regulatory frameworks for brain and nervous system therapies.
PerturbAI and OpenAI reported that an ensemble of distributed reasoning agents parsed a whole-brain perturbation dataset in 32 minutes, recovering known mechanisms and predicting unseen cellular responses.
The FDA accepted Biohaven's resubmitted application for Vyglxia to treat spinocerebellar ataxia, a hereditary neurodegenerative disease with no approved therapies.
Celltrion has acquired global rights to KG013, a preclinical antibody targeting the signaling protein APRIL to treat autoimmune kidney conditions like IgA nephropathy, with Kaigene retaining an option to co-market the drug in South Korea.
Menarini subsidiary Stemline Therapeutics has secured exclusive worldwide rights to GIM-621, an experimental oral small-molecule cancer immunotherapy, in a deal worth up to $1.1 billion.
AbbVie reported that its experimental therapy met the primary endpoint of a Phase 3 study by significantly reducing inflammatory lumps and abscesses in patients with a chronic inflammatory skin condition.
BioNTech has formed a clinical partnership with Gilead Sciences to evaluate its experimental cancer therapy in combination with Gilead's approved oncology drug in advanced breast cancer.
Medical trade groups and digital health advocates are staking out competing positions as the FDA considers evidence standards for generative AI medical devices, including prescription bots.
Roche has discontinued RG6540, a Phase 1 dual-targeting CD19 and CD20 off-the-shelf cell therapy acquired in its $1.5 billion buyout of Poseida Therapeutics, while affirming ongoing interest in the underlying platform.
OpenDVP provides an open-source pipeline that couples single-cell imaging tools like QuPath and napari with standardized spatial data structures from scverse to enable deep visual proteomics.
CauTrigger models biological state transitions as multi-step causal cascades, filtering out spurious correlations across large-scale molecular profiles.
Researchers have developed fastGxE, a computational method designed to identify how genetic variants interact with environmental factors to shape human traits at biobank scale.
Targeted mass spectrometry on human macrophages infected with Mycobacterium tuberculosis revealed that fewer than 1% of pathogen peptides identified as strong HLA-A*02:01 binders in yeast-display screens were actually presented on MHC class I molecules.
Researchers built a biophysical model constrained by individual structural connectomes to jointly generate single-trial electroencephalography (EEG) signals and reaction times during a motion discrimination task.
Researchers introduced Panagram, an open-source software pipeline that compares full collections of diverse genomes across a species (pangenomes) using shared DNA word counts instead of computationally expensive sequence alignments.
A diagnostic framework called IGLOO evaluates gradient-based residue attributions against synthetic protein fitness landscapes with known ground-truth residue contributions.